TGTX.NASDAQTg Therapeutics, INC
Form 4: TG Therapeutics Director Daniel Hume Transfers Shares to Trust
Sentiment:
SEC Form 4 Filing
Director Daniel Hume reports a transfer of TG Therapeutics stock to a trust for the benefit of his dependents.
Summary
- On March 17, 2025, Daniel Hume, a director of TG Therapeutics, Inc., transferred 62,459 shares of common stock to a trust for the benefit of his dependents.
- The transaction was reported on March 18, 2025.
- Following the transaction, Mr. Hume beneficially owns 178,030 shares of TG Therapeutics, Inc., including restricted common stock that vests over various time periods.
Sentiment
Score: 5
Explanation: The document is a routine filing related to a stock transfer, indicating a neutral sentiment.
Stakeholder Impact
- The transfer of shares to a trust may have a minor impact on shareholders, but is unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 03/17/2025 | Date of stock transfer to a trust |
| 03/18/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.